IQVIA Exec On Putting India Firmly In IO Trials Reckoning
Executive Summary
An IQVIA executive in Asia sees scope for India to figure routinely on the radar of sponsors for immuno-oncology trials and outlines how some gaps to get there can be plugged.
You may also be interested in...
Opdivo Secures India Patent, Fends Off Multi-Party Opposition
India clears Opdivo patent, turning down pre-grant representations from four opposing parties including Dr Reddy's. The patent office rejected the opponents' arguments including those around obviousness and "inherent anticipation."
COVID-19, Lockdown Affect Trials in India But Coping Efforts In Hand
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.
Roche’s Tecentriq Gets Another Indication In India But Pricing Hurts
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.